Background/Objectives: Acute liver failure (ALF) is a life-threatening condition with high mortality in nontransplant candidates. Therapeutic plasma exchange (TPE) has emerged as a promising intervention for removing inflammatory mediators and toxic metabolites. In Latin America, data on the efficacy of TPE in ALF patients are limited. This real-world study aimed to compare 30-day survival outcomes between patients receiving standard medical treatment (SMT) and those receiving SMT plus TPE. Methods: We analyzed 25 ALF patients admitted to the tertiary intensive care unit (ICU) of Hospital Juárez of Mexico City, Mexico, from 2018 to 2024. Patients received either standard medical treatment (SMT group, n = 12) or SMT with TPE (TPE group, n = 13), including high-volume TPE (n = 8) and standard-volume TPE (n = 5). Survival analysis was performed via Kaplan–Meier estimates, and binomial regression analysis was run to estimate the mortality probability stratified by the hepatic encephalopathy grade. Results: At 30 days, survival was significantly greater in the TPE group (92%) than in the SMT group (50%) (p = 0.02). The greatest survival benefit was observed in patients with Grade 4 encephalopathy. The ICU stay was longer in the TPE group, reflecting the complexity of ALF management. Conclusions: TPE significantly improves 30-day survival in ALF patients compared with SMT alone, supporting its role as an adjunct therapy. Further studies are needed to refine patient selection and optimize treatment protocols.
Key Points: The modified renal angina index outperformed prior indices for early severe AKI prediction in critically ill adults. Combining modified renal angina index with [tissue inhibitor of metalloproteinase-2]×[IGF binding protein 7] improved area under the receiver operating characteristic curve, although not statistically significant, requiring external validation. Early AKI detection supports timely nephroprotective actions and individualized management in critical care. Background: Several renal angina indices (RAIs) have been developed to stratify AKI risk in critically ill populations. However, limited evidence supports whether incorporating urinary biomarkers enhances predictive performance. This study aimed to evaluate the diagnostic accuracy of three RAIs, with and without urinary biomarkers integration, for predicting severe AKI (defined as Kidney Disease Improving Global Outcomes stages 2–3) in critically ill adults. Methods: In this prospective, multicenter diagnostic study, we assessed the ability of three RAIs to predict severe AKI, defined as Kidney Disease Improving Global Outcomes stages 2–3, within 72 hours of intensive care unit admission. We further evaluated whether the addition of urinary biomarkers improve predictive accuracy, using area under the receiver operating characteristic curve (AUC) and net reclassification improvement (NRI). Results: We enrolled 134 critically ill patients, of whom 15% developed severe AKI within 72 hours. Diagnostic performance of RAIs and urinary biomarkers alone was modest (AUC: Matsuura RAI, 0.63; Del Toro RAI, 0.71; and modified RAI [mRAI], 0.76). Incorporating urinary biomarkers improves the predictive performance of all RAIs, particularly enhancing specificity. Among biomarkers assessed, (tissue inhibitor of metalloproteinase-2 [TIMP‐2])×(IGF binding protein 7 [IGFBP7]) demonstrated the greatest capacity to reclassify patients toward event prediction across RAI models. The combination of mRAI with [TIMP‐2]×[IGFBP7] yields the highest absolute predictive performance (AUC, 0.82; 95% confidence interval, 0.72 to 0.93). Conclusions: Sequential risk stratification combining clinical RAIs with targeted urinary biomarkers profiling significantly improves early prediction of severe AKI in critically ill adults' patients. Although RAIs and urinary biomarkers alone show limited predictive accuracy, their integration—particularly mRAI plus [TIMP‐2]×[IGFBP7]—optimizes discrimination and may facilitate earlier intervention in high-risk intensive care unit adult patients.
Urgent-start hemodialysis often involves severe biochemical abnormalities but is associated with a high risk of complications. Currently, no tool has been validated to predict post-hemodialysis urea and electrolytes in acute settings from prescription data alone. In this ambispective, two-phase study, we developed and validated a model to predict post-hemodialysis blood urea nitrogen and electrolytes using only prescription parameters in patients with urgent hemodialysis indications and those at risk for dialysis disequilibrium syndrome, severe hyponatremia, or hyperkalemia. The model was validated through statistical assessment of correlation and agreement. The model was integrated into a free, user-friendly web application (Adequator app®). The development cohort included 303 treatments in 42 chronic hemodialysis patients. Dialyzer clearance, which was calculated via formal urea kinetic modeling, demonstrated excellent correlation and agreement with the proposed model (r = 0.99; 95% CI: 0.99 to 0.99) and a bias of 0.23 ± 1.2 ml/min (95% CI: −2.17 to 2.63). The validation cohort included 44 urgent hemodialysis sessions in 30 patients with chronic kidney disease or acute kidney injury and severe electrolyte abnormalities or at risk of dialysis disequilibrium syndrome. The predicted post-hemodialysis, blood urea nitrogen, sodium, and potassium levels strongly correlated with the measured values: r = 0.96 (95% CI: 0.93 to 0.98), r = 0.96 (95% CI: 0.94 to 0.98), and r = 0.84 (95% CI: 0.73 to 0.91), respectively. Agreement was also high, with biases of 0.4 ± 9.4 mg/dL (95% CI: −19.0 to 18.1) for blood urea nitrogen, −0.6 ± 1.6 mEq/L (95% CI: −3.8 to 2.5) for sodium, and 0.17 ± 0.4 mEq/L (95% CI: 0.6 to 0.9) for potassium. Among patients at risk of dialysis disequilibrium syndrome, 92% achieved the target blood urea nitrogen reduction ( < 40%) without severe neurological events. The sodium correction remained below 6 mEq/L, and potassium normalized in all the cases. A prescription-based model can reliably predict post-Hemodialysis urea and electrolyte values in urgent dialysis settings. The Adequator App HD-Predictor ( https://adequatorapp.com/hd-predictor ) offers a non-invasive, accessible tool to guide individualized prescriptions, enhancing safety and precision in high-risk clinical scenarios.
Background/Objectives: Acute liver failure (ALF) is a life-threatening condition with high mortality in nontransplant candidates. Therapeutic plasma exchange (TPE) has emerged as a promising intervention for removing inflammatory mediators and toxic metabolites. In Latin America, data on the efficacy of TPE in ALF patients is limited. This real-world study aimed to compare 30-day survival outcomes between patients receiving standard medical treatment (SMT) and those receiving SMT plus TPE. Methods: We analyzed 25 ALF patients admitted to the tertiary intensive care unit (ICU) of Hospital Juárez of Mexico City, Mexico, from 2018–2024. Patients received either standard medical treatment (SMT group, n=12) or SMT with TPE (TPE group, n=13), including high-volume TPE (n=8) and standard-volume TPE (n=5). Survival analysis was performed via Kaplan‒Meier estimates, and binomial regression analysis was run to estimate the mortality probability stratified by the hepatic encephalopathy grade. Results: At 30 days, survival was significantly greater in the TPE group (92%) than in the SMT group (50%) (p = 0.02). The greatest survival benefit was observed in patients with Grade 4 encephalopathy. The ICU stay was longer in the TPE group, reflecting the complexity of ALF management. Conclusion: TPE significantly improves 30-day survival in ALF patients compared with SMT alone, supporting its role as an adjunct therapy. Further studies are needed to refine patient selection and optimize treatment protocols.
6 June 2024 in Revista de la Sociedad Ecuatoriana de Nefrología, Diálisis y Trasplante
Introduction: Critically ill patients who survive a severe episode of Acute Kidney Injury (AKI) recover sufficient renal function to allow withdrawal of Renal Replacement Therapy (RRT). However, the criteria for deciding its withdrawal need to be standardized in clinical practice. The study aimed to determine the factors associated with failure to disconnect in patients on continuous renal replacement therapy. Methods: This observational study was carried out in adult patients hospitalized in the intensive care service of the National Institute of Nutrition "Salvador Zubirán" in Mexico between October and December 2023 who required continuous renal replacement therapy. Retrospective data were collected, including demographic characteristics, comorbidities, type of renal replacement therapy, and clinical outcome. The SOFA score was used to assess disease severity. Results: A total of 18 patients were analyzed, 14 with unsuccessful disconnection and 4 with successful disconnection, with an average stay of 14±8 days in the ICU; 72% were men, 44% with a history of diabetes, and 72.2% with a history of high blood pressure. A total of 94.4% with vasopressor requirement and invasive mechanical ventilation. The primary RRT modality was CVVHDF (88.9%). The main indications for initiation were overload (38.9%) and anuria (44.4%). There were no differences between population characteristics or RRT modality. Differences in mortality were evident, probably explained by the greater severity of the patients, as evidenced by the more excellent SOFA upon admission (P=0.001). Conclusion: Patients who were unable to disconnect from the replacement therapy program had higher mortality. The factor that most contributed to this outcome was a higher SOFA score.